GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

24 Mar 2016 15:00

RNS Number : 2424T
AstraZeneca PLC
24 March 2016
 

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 24 March 2016, the individuals listed below, who are all persons discharging managerial responsibilities, were granted awards over the Company's ordinary shares or American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Investment Plan (AZIP). Two ADSs equal one ordinary share.

 

 

Name

Shares awarded under AZDBP

Shares awarded under AZPSP

Shares awarded under AZIP

Award price per share

 

Pascal Soriot

 

17,352

 

129,713

 

21,618

 

3923p

 

Marc Dunoyer

 

8,798

 

54,101

 

9,016

 

3923p

 

Sean Bohen

 

1,496

 

78,155

 

 

13,025

 

$28.19

 

Luke Miels

 

2,107

 

30,225

 

5,037

 

3923p

 

The AZDBP award represents the portion of each individual's annual bonus for 2015 that they are required to defer into shares. The shares are subject to a three-year holding period (24 March 2016 to 23 March 2019).

 

The AZPSP award is subject to a combination of performance measures focused on our scientific, commercial and financial performance assessed over a three-year performance period (1 January 2016 to 31 December 2018). The award will vest on the third anniversary of the date on which it was granted, except for awards to Executive Directors, which will be subject to a further two-year holding period before the award vests.

 

The AZIP award is subject to two performance hurdles relating to dividend and dividend cover over a four-year performance period (1 January 2016 to 31 December 2019). The award is subject to a four-year holding period, commencing at the end of the performance period.

 

Details of the performance measures that relate to the AZPSP and AZIP awards can be found in the Directors' Remuneration Report of the AstraZeneca Annual Report and Form 20-F Information 2015 which is available on the Company's website at www.astrazeneca-annualreports.com/2015/.

 

 

 

A C N Kemp

Company Secretary

24 March 2016

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUSASRNUAOUAR
Date   Source Headline
16th Mar 201711:00 amRNSNotice of AGM
15th Mar 20177:00 amRNSLYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
8th Mar 20177:00 amRNSFiling of Form 20-F with SEC
7th Mar 20172:30 pmRNSAnnual Financial Report
6th Mar 20177:00 amRNSDirectorate Change
3rd Mar 20177:00 amRNSALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
1st Mar 20174:30 pmRNSTotal Voting Rights
28th Feb 20177:02 amRNSFDA approves once-daily Qtern for type-2 diabetes
24th Feb 201712:32 pmRNSCHMP positive opinion for ZS-9 in hyperkalaemia
20th Feb 20177:00 amRNSAZ licenses Zoladex to TerSera for the US & Canada
17th Feb 20177:00 amRNSLynparza positive in metastatic BRCA breast cancer
16th Feb 201712:01 pmRNSSILIQ (BRODALUMAB) APPROVED BY US FDA
2nd Feb 20177:00 amRNSAZN: FY16 and Q4 2016 Results
1st Feb 20174:00 pmRNSTotal Voting Rights
26th Jan 201710:00 amRNSSYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17th Jan 20177:00 amRNSAZ 1st-line lung cancer immuno-oncology programme
3rd Jan 20174:00 pmRNSTotal Voting Rights
23rd Dec 20167:00 amRNSAZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16th Dec 20161:00 pmRNSDirector/PDMR Shareholding
9th Dec 20163:05 pmRNSFDA accepts durvalumab for BLA in bladder cancer
6th Dec 20169:30 amRNSTagrisso data shows superiority over chemotherapy
5th Dec 20167:00 amRNSAZ completes agreement for Rhinocort Aqua rights
1st Dec 20164:00 pmRNSBlock listing Interim Review
1st Dec 20163:00 pmRNSTotal Voting Rights
22nd Nov 20167:00 amRNSAZ head and neck cancer trials resume enrolment
17th Nov 20167:00 amRNSAZ out-licensing deal with Allergan completed
10th Nov 20167:04 amRNSYear-To-Date and Q3 2016 Results
9th Nov 20167:00 amRNSDirectorate Change
1st Nov 20163:30 pmRNSDealing by Person Closely Associated
1st Nov 20163:00 pmRNSTotal Voting Rights
31st Oct 20161:47 pmRNSAZ completes US Aralez agreement for Toprol-XL
27th Oct 20164:51 pmRNSAstraZeneca Head and Neck Cancer Trials
26th Oct 20167:00 amRNSPositive results in AstraZeneca Lynparza trial
18th Oct 20167:00 amRNSFDA accepts for review ZS-9 NDA for hyperkalaemia
7th Oct 20167:00 amRNSAZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
4th Oct 20167:05 amRNSAZ agreement with Aralez for Toprol-XL in US
4th Oct 20167:00 amRNSAstraZeneca reports top-line EUCLID results in PAD
3rd Oct 20163:00 pmRNSTotal Voting Rights
3rd Oct 20167:00 amRNSMedImmune out-licenses medicine to Allergan
28th Sep 20167:00 amRNSCHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26th Sep 20164:00 pmRNSDirector/PDMR Shareholding
22nd Sep 201611:00 amRNSDirector Declaration
1st Sep 20162:30 pmRNSTotal Voting Rights
1st Sep 20167:00 amRNSAstraZeneca Completes Aspen Agreement
24th Aug 20167:00 amRNSAZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.